News and Press Releases
Ellipses In-Licences First in Class Novel Immuno-Oncology Agent with Potential as a Next Generation Checkpoint Inhibitor
11 February 2025 -- London, UK -- Ellipses Pharma Limited, a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced...
Category: BioManufacturing, Drug Discovery, Other, Pharmaceutical
Posted: February 11, 2025
Kite Presents New Data on Patient Outcomes with CAR T-Cell Therapy at the 7th European CAR T-Cell Meeting, 6-8 February, Strasbourg, France
6 February 2025 -- Stockley Park, UK -- Kite, a Gilead Company, will share four posters that add to the growing body of evidence to support the clinical use of...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 6, 2025
Novel Findings Using the Parsortix System Demonstrating Role of CTC:B Cell Clusters in Driving Cancer Progression
Findings may enable the development of novel drugs to target B cell and CTC cluster interactions to suppress cancer metastasis This pivotal work is likely to stimulate further interest in...
Category: Drug Discovery, Other, Pharmaceutical
Posted: February 6, 2025
BioMed X Institute and Merck Successfully Complete Extrachromosomal DNA in Cancer Research Project
The research of BioMed X team EDC - Extrachromosomal DNA in Cancer - has uncovered critical insights into the mechanisms driving extrachromosomal DNA (ecDNA) formation and maintenance, offering potential avenues for...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 6, 2025
Cognizant and Gilead Expand Partnership to Drive Greater Value Through Advanced Technology Applications
Cognizant will provide AI-driven solutions to enhance customer service, employee engagement, and business value 30 January 2025 -- New Jersey, US -- Cognizant has announced an expansion of its longstanding relationship...
Category: Biotechnology, Drug Discovery, Logistics, Other, Pharmaceutical
Posted: January 30, 2025
Office Cognizant Technology Solutions World Headquarters Glenpointe Centre West 500 Frank W Burr Blvd Teaneck 07666 NJ
Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics
30 January 2025 -- Espoo, Finland -- Orion Corporation and Invenra Inc, an innovative biotechnology company with proprietary technologies for discovering novel therapeutics, today announced that they have entered into...
Category: Drug Discovery, Other, Pharmaceutical
Posted: January 30, 2025
Owkin Announces First Patient Dosed in Phase I AI-optimized Clinical Trial of OKN4395, a First-in-Class EP2/EP4/DP1 Triple Inhibitor for Patients with Solid Tumors
OKN4395 is the first Owkin development program to leverage K1.0, Owkin’s AI-powered Operating System, from asset selection to clinical development optimization This asset is a highly selective triple inhibitor of...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 30, 2025
NEW RESULTS FOR dual analysis of CTC-DNA and ctDNA using Illumina assay and sequencing platform
Findings in lung cancer show that CTCs can provide additional biomarkers not found in ctDNA from single blood sample ANGLE invited to present data at EACR-Illumina webinar on 6 February...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: January 29, 2025
Pfizer’s BRAFTOVI Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
Clinically meaningful and statistically significant results from the Phase 3 BREAKWATER trial show objective response rate of 61% with Pfizer’s BRAFTOVI combination regimen compared to 40% with investigator’s choice of...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 25, 2025
Clinical Trial Powered by Parsortix System Provides First-in-Class Data for Novel Approach to Cancer Treatment
Parsortix system used to identify patients with highly metastatic CTC clusters for targeted treatment New treatment strategy provides ‘uncharted opportunity’ to target metastasis responsible for the vast majority of cancer...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 24, 2025
HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
Indication expands to include treatment-naïve patients The 2021 conditional approval in previously treated patients converted to full approval. 14 January 2025 -- Hong Kong, Shanghai, and New Jersey, US --...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 14, 2025
BioMed X Institute Launches New Collaboration with Daiichi Sankyo in Cancer Therapy
German research institute BioMed X started a new partnership with Daiichi Sankyo, a Japanese pharmaceutical company, to advance the development of bi- and multi-specific biologics for treating solid tumors 14 January...
Category: Drug Discovery, Other, Pharmaceutical
Posted: January 14, 2025
GILEAD AND LEO PHARMA ENTER INTO STRATEGIC PARTNERSHIP TO ACCELERATE DEVELOPMENT OF ORAL STAT6 PROGRAM WITHPOTENTIAL IN MULTIPLE INFLAMMATORY DISEASES
11 January 2025 – Foster City, California, US and Ballerup, Denmark – Gilead Sciences, Inc. (Nasdaq: GILD) andLEO Pharmatoday announced a strategic partnership to accelerate the development and commercialization of...
Category: Pharmaceutical
Posted: January 13, 2025
Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma
Approval based on positive pivotal ICARIA-MM phase 3 study using the China-based IsaFiRsT real-world study as bridging data, which demonstrated Sarclisa and the standard treatment Pd, improved responses and long-term...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 13, 2025
Gilead and Leo Pharma Enter into Strategic Partnership to Accelerate Development of Oral STAT6 Program with Potential in Multiple Inflammatory Diseases
Strategic Partnership Strengthens Gilead’s Inflammation Research Portfolio with the Addition of LEO Pharma’s Preclinical Oral STAT6 Program, Including Targeted Protein Degraders Gilead Will Have Exclusive Global Rights to the STAT6...
Category: Drug Discovery, Other, Pharmaceutical
Posted: January 11, 2025
